|Company - Telephone|
Products, Fields of specialty
|Alpha Tau Medical - (972).|
Alpha DaRT technology utilizes Alpha radiation to treat cancer. DaRT (Diffusing Alpha-emitters Radiation Therapy) treats solid tumors with interstitial radioactive seeds that continually release short-lived alpha-emitting atoms into the tumor.
|BioLineRx - (972).2.5489100|
Motixafortide (BL-8040) cancer therapy platform currently evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA and chemotherapy. Immunotherapy treatment for multiple solid tumors.
|Biokine Therapeutics - (972).8.9301015|
Drugs to treat inflammatory diseases and cancer by targeting immune and tumor cell migration via chemokines. BKT104 targeting production of TNF-Alfa. BKT140, a CXCR4 chemokine receptor antagonist for treatment of tumor growth and metastasis.
|Enlivex Therapeutics - (972).2.6708072|
Development of a drug pipeline for macrophage reprogramming in solid cancers, Sepsis, COVID-19 and other indications. Allocetra for the reprogramming of diseased macrophages in patients with sepsis or COVID-19.
|Fore - (972).2.5001100|
Technology that identifies tumor specific driver mutations based on a functional assay that detects disregulated translocation of mutated signaling proteins to the nucleus. Assay can measure impact of a drug on a specific tumor.
|Immunovative Therapies - (972).2.6505088|
immunotherapy products with unprecedented effects in late stage cancer and HIV positive patients. Therapeutic anti-tumor vaccine developed based on the "Mirror Effect“ which opens a pathway to treating patients with metastatic cancer that have failed available therapy options. Elicits a GVT-like mechanism without the GVHD toxicity.
|Izun Pharmaceuticals - (972).2.5861814|
IZN-6N4 to prevent and treat radiation-induced severe oral mucositis (SOM) in head and neck cancer patients.
|Vascular Biogenics - (972).3.6346450|
Lead product candidate VB-111 is a targeted anti-cancer biologic agent that is positioned to potentially treat a wide range of solid tumors. Developing proprietary monoclonal antibodies targeting MOSPD2 for immune inflammatory diseases and bi-specific antibodies for cancer.